Chembio Diagnostics Trading Up 5.6 %
Shares of Chembio Diagnostics stock opened at $0.29 on Monday. The company has a 50-day moving average of $0.33 and a two-hundred day moving average of $0.57. The stock has a market cap of $10.46 million, a PE ratio of -0.24 and a beta of 1.72. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01. Chembio Diagnostics has a 12-month low of $0.23 and a 12-month high of $2.33.
Institutional Trading of Chembio Diagnostics
Several institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC increased its position in Chembio Diagnostics by 98.0% during the 3rd quarter. Signaturefd LLC now owns 69,300 shares of the company’s stock worth $25,000 after purchasing an additional 34,300 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Chembio Diagnostics by 383.4% during the 3rd quarter. Renaissance Technologies LLC now owns 113,600 shares of the company’s stock worth $41,000 after purchasing an additional 90,100 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Chembio Diagnostics during the first quarter worth about $102,000. Finally, Vanguard Group Inc. raised its position in shares of Chembio Diagnostics by 41.4% in the third quarter. Vanguard Group Inc. now owns 1,562,014 shares of the company’s stock valued at $564,000 after buying an additional 457,450 shares during the last quarter. Hedge funds and other institutional investors own 8.63% of the company’s stock.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.
- Get a free copy of the StockNews.com research report on Chembio Diagnostics (CEMI)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.